

Buprenorphine (Transtec[®]) patch
Napp Pharmaceuticals

No. 116/04

Summary of Recommendation

13 September, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Buprenorphine (Transtec[®]) patch is not recommended for use within NHS Scotland for the treatment of moderate to severe cancer pain and severe pain that does not respond to non-opioid analgesics.

No comparative data have been provided with alternative transdermal or oral opioid preparations. The case for buprenorphine patches as a cost-minimising option when compared to the other transdermal opioid preparation marketed in the UK was not demonstrated.

The licence holder has indicated their decision to resubmit.

Professor David H Lawson
Chairman